These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 9252981)

  • 1. In vivo occupancy of D2 dopamine receptors by nafadotride.
    Levant B; Vansell NR
    Neuropsychopharmacology; 1997 Aug; 17(2):67-71. PubMed ID: 9252981
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nafadotride, a potent preferential dopamine D3 receptor antagonist, activates locomotion in rodents.
    Sautel F; Griffon N; Sokoloff P; Schwartz JC; Launay C; Simon P; Costentin J; Schoenfelder A; Garrido F; Mann A
    J Pharmacol Exp Ther; 1995 Dec; 275(3):1239-46. PubMed ID: 8531087
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparative in vitro and in vivo pharmacological characterization of the novel dopamine D3 receptor antagonists (+)-S 14297, nafadotride, GR 103,691 and U 99194.
    Audinot V; Newman-Tancredi A; Gobert A; Rivet JM; Brocco M; Lejeune F; Gluck L; Desposte I; Bervoets K; Dekeyne A; Millan MJ
    J Pharmacol Exp Ther; 1998 Oct; 287(1):187-97. PubMed ID: 9765337
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vivo occupancy of D2 dopamine receptors by 7-OH-DPAT.
    Levant B; Bancroft GN; Selkirk CM
    Synapse; 1996 Sep; 24(1):60-4. PubMed ID: 9046077
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nafadotride administration increases D1 and D1/D2 dopamine receptor mediated behaviors.
    Dall'Olio R; Gaggi R; Voltattorni M; Tanda O; Gandolfi O
    Behav Pharmacol; 2002 Dec; 13(8):633-8. PubMed ID: 12478213
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alterations in local cerebral glucose utilization produced by D3 dopamine receptor-selective doses of 7-OH-DPAT and nafadotride.
    Levant B; Cross RS; Pazdernik TL
    Brain Res; 1998 Nov; 812(1-2):193-9. PubMed ID: 9813322
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The dopamine D3 receptor antagonist nafadotride inhibits development of locomotor sensitization to amphetamine.
    Richtand NM; Logue AD; Welge JA; Perdiue J; Tubbs LJ; Spitzer RH; Sethuraman G; Geracioti TD
    Brain Res; 2000 Jun; 867(1-2):239-42. PubMed ID: 10837819
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduced expression of haloperidol conditioned catalepsy in rats by the dopamine D3 receptor antagonists nafadotride and NGB 2904.
    Banasikowski TJ; Beninger RJ
    Eur Neuropsychopharmacol; 2012 Oct; 22(10):761-8. PubMed ID: 22410316
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of dopamine D3 receptor antagonists on spontaneous and agonist-reduced motor activity in NMRI mice and Wistar rats: comparative study with nafadotride, U 99194A and SB 277011.
    Gyertyán I; Sághy K
    Behav Pharmacol; 2004 Jul; 15(4):253-62. PubMed ID: 15252275
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sex differences in nicotine sensitization and conditioned hyperactivity in adolescent rats neonatally treated with quinpirole: role of D2 and D3 receptor subtypes.
    Sheppard B; Lehmann J; Cope ZA; Brown RW
    Behav Neurosci; 2009 Dec; 123(6):1296-308. PubMed ID: 20001113
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential effects of dopamine receptor subtype blockade on performance of rats in a reaction-time paradigm.
    Smith AD; Smith DL; Zigmond MJ; Amalric M; Koob GF
    Psychopharmacology (Berl); 2000 Mar; 148(4):355-60. PubMed ID: 10928307
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased levels of proneurotensin/neuromedin N mRNA in rat striatum and nucleus accumbens induced by 7-OH-DPAT and nafadotride.
    Levant B; Garimelli B; Shafer RA; Merchant KM
    Neuropsychopharmacology; 1999 Aug; 21(2):304-11. PubMed ID: 10432478
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anxiolytic-like effect of nafadotride and PNU 99194A, dopamine D3 receptor antagonists in animal models.
    Rogóz Z; Kłodzińska A; Maj J
    Pol J Pharmacol; 2000; 52(6):459-62. PubMed ID: 11334239
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neurochemical characteristics of amisulpride, an atypical dopamine D2/D3 receptor antagonist with both presynaptic and limbic selectivity.
    Schoemaker H; Claustre Y; Fage D; Rouquier L; Chergui K; Curet O; Oblin A; Gonon F; Carter C; Benavides J; Scatton B
    J Pharmacol Exp Ther; 1997 Jan; 280(1):83-97. PubMed ID: 8996185
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evidence for a functional role of the dopamine D3 receptors in the cerebellum.
    Barik S; de Beaurepaire R
    Brain Res; 1996 Oct; 737(1-2):347-50. PubMed ID: 8930390
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Heterogeneity of behavioural profile between three new putative selective D3 dopamine receptor antagonists using an ethologically based approach.
    Clifford JJ; Waddington JL
    Psychopharmacology (Berl); 1998 Apr; 136(3):284-90. PubMed ID: 9566814
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acute neurobehavioral effects of toluene: involvement of dopamine and NMDA receptors.
    Lo PS; Wu CY; Sue HZ; Chen HH
    Toxicology; 2009 Nov; 265(1-2):34-40. PubMed ID: 19765629
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Day/night differences in D1 but not D2 DA receptor protection from EEDQ denaturation in rats treated with continuous cocaine.
    Burger LY; Martin-Iverson MT
    Synapse; 1993 Jan; 13(1):20-9. PubMed ID: 8093985
    [TBL] [Abstract][Full Text] [Related]  

  • 19. N-(p-isothiocyanatophenethyl)spiperone, a selective and irreversible antagonist of D2 dopamine receptors in brain.
    Xu SX; Hatada Y; Black LE; Creese I; Sibley DR
    J Pharmacol Exp Ther; 1991 May; 257(2):608-15. PubMed ID: 1674530
    [TBL] [Abstract][Full Text] [Related]  

  • 20. D3 receptor test in vitro predicts decreased cocaine self-administration in rats.
    Caine SB; Koob GF; Parsons LH; Everitt BJ; Schwartz JC; Sokoloff P
    Neuroreport; 1997 Jul; 8(9-10):2373-7. PubMed ID: 9243643
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.